Method for treating psoriasis by administering an anti-IL-12 antibody
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
1. A method for treating psoriasis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12antibody, comprising a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6, wherein the antibody is a variant of the antibody comprising the heavy chain CDR1 amino acid sequence of SEQ ID NO:1, the heavy chain CDR2 amino acid sequence of SEQ ID NO:2, the heavy chain CDR3 amino acid sequence of SEQ ID NO:3, the light chain CDR1 amino acid sequence of SEQ ID NO:4, the light chain CDR2 amino acid sequence of SEQ ID NO:5, and the light chain CDR3 amino acid sequence of SEQ ID NO:6, to said animal.
2. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.
3. The method according to claim 1 , wherein said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intraspinal, intrasynovial, rectal, buccal, sublingual, intranasal, and transdermal.
4. The method according to claim 1 , further comprising administering at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.